PSFG
IRMD icon

Park Square Financial Group’s iRadimed IRMD Stock Holding History

Park Square Financial Group’s Portfolio IRMD Stock Details IRMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-48
Closed -$2.87K – 608
2025
Q2 		$2.87K Hold
48
– – ﹤0.01% 824
2025
Q1 		$2.52K Hold
48
– – ﹤0.01% 830
2024
Q4 		$2.64K Buy
+48
New +$2.53K ﹤0.01% 799

Other funds holding IRMD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NTCM
Nine Ten Capital Management Chicago, Illinois $315M AUM 62.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
CCM
Copeland Capital Management Conshohocken, Pennsylvania $4.5B AUM 18.67% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Park Square Financial Group's IRMD Position: Q3 2025 in Review

Park Square Financial Group sold out of iRadimed (IRMD) in Q3 2025, closing a stake of 48 shares — an estimated $2.87K sold.

Park Square Financial Group first reported a position in IRMD in Q4 2024 and held it in 3 quarters. The position peaked at $2.87K in Q2 2025. 185 funds tracked by Wall St. Rank hold IRMD as of Q3 2025.

  • Park Square Financial Group reported no remaining iRadimed position as of Q3 2025 after selling out during the quarter.
  • Park Square Financial Group sold 48 iRadimed shares in Q3 2025, an estimated $2.87K.
  • Park Square Financial Group first reported a position in iRadimed in Q4 2024 and held it in 3 quarters.
  • Park Square Financial Group's iRadimed position peaked at $2.87K in Q2 2025.
  • 185 funds tracked by Wall St. Rank held iRadimed as of Q3 2025.

Based on Park Square Financial Group's 13F filing for Q3 2025, filed 12 Nov 2025.